Free Trial
→ Trump's Law S.1582: $21T Dollar Revolution Coming (From Brownstone Research) (Ad)tc pixel Free ABVX Stock Alerts

Abivax (ABVX) Financials

Abivax logo
$90.76 +0.29 (+0.32%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$91.96 +1.21 (+1.33%)
As of 10/24/2025 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Abivax

Annual Income Statements for Abivax

This table shows Abivax's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -48 -65 -163 -182
Consolidated Net Income / (Loss)		 -48 -65 -163 -182
Net Income / (Loss) Continuing Operations		 -48 -65 -163 -182
Total Pre-Tax Income 		-48 -65 -163 -182
Total Operating Income		 -47 -69 -141 -179
Total Gross Profit		 0.00 0.00 -7.11 -6.16
Total Revenue		 0.00 0.00 -7.11 -6.16
Operating Revenue		 0.00 0.00 -7.11 -6.16
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 47 69 134 173
Selling, General & Admin Expense		 6.32 8.01 25 34
Research & Development Expense		 54 52 114 152
Other Operating Expenses / (Income)		 -14 -4.90 -5.11 -13
Impairment Charge		 0.00 15 0.00 0.00
Total Other Income / (Expense), net		 -1.19 4.38 -23 -3.37
Interest Expense		 4.03 7.51 31 18
Interest & Investment Income		 2.84 12 8.31 14
Income Tax Expense		 0.00 0.00 0.00 0.00
Weighted Average Basic Shares Outstanding		 15.46M 19.09M 43.07M 63.05M
Diluted Earnings per Share		 ($2.75) ($3.40) ($3.79) ($2.90)
Weighted Average Diluted Shares Outstanding		 15.46M 19.09M 43.07M 63.05M
Weighted Average Basic & Diluted Shares Outstanding		 - - 62.93M 63.35M

Quarterly Income Statements for Abivax

No quarterly income statements for Abivax are available.

Annual Cash Flow Statements for Abivax

This table details how cash moves in and out of Abivax's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 36 -68 -144 -112
Net Cash From Operating Activities		 -51 -58 -190 -154
Net Cash From Continuing Operating Activities		 -51 -58 -190 -154
Net Income / (Loss) Continuing Operations		 -48 -65 -163 -182
Consolidated Net Income / (Loss)		 -48 -65 -163 -182
Depreciation Expense		 0.34 0.52 0.78 1.14
Non-Cash Adjustments To Reconcile Net Income		 -1.70 6.16 -32 26
Changes in Operating Assets and Liabilities, net		 -1.57 0.08 4.14 1.47
Net Cash From Investing Activities		 -7.05 0.33 -16 -0.66
Net Cash From Continuing Investing Activities		 -0.05 0.33 -16 -0.66
Purchase of Property, Plant & Equipment		 -0.05 - - -0.66
Acquisitions		 - - - 0.00
Sale and/or Maturity of Investments		 0.00 - - 0.00
Net Cash From Financing Activities		 94 -10 62 38
Net Cash From Continuing Financing Activities		 72 -10 62 38
Repayment of Debt		 -2.44 -10 - -12
Issuance of Debt		 - 0.00 62 50
Issuance of Common Equity		 79 - - 0.45
Effect of Exchange Rate Changes		 - - - 2.47
Cash Interest Paid		 - - - 7.97
Cash Interest Received		 - 0.02 2.65 8.47

Quarterly Cash Flow Statements for Abivax

No quarterly cash flow statements for Abivax are available.

Annual Balance Sheets for Abivax

This table presents Abivax's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 124 81 362 212
Total Current Assets		 85 39 306 169
Cash & Equivalents		 69 29 279 149
Accounts Receivable		 17 9.88 27 20
Plant, Property, & Equipment, net		 0.23 -0.80 -5.78 -3.51
Plant, Property & Equipment, gross		 0.23 -0.80 -5.78 -3.51
Total Noncurrent Assets		 74 105 218 220
Goodwill		 36 20 20 19
Intangible Assets		 48 72 171 189
Noncurrent Deferred & Refundable Income Taxes		 -0.18 -0.14 -0.06 0.00
Other Noncurrent Operating Assets		 -9.72 13 27 11
Total Liabilities & Shareholders' Equity		 124 143 518 385
Total Liabilities		 83 70 138 160
Total Current Liabilities		 24 38 88 69
Short-Term Debt		 0.71 21 33 22
Accounts Payable		 23 17 52 45
Other Current Liabilities		 0.00 0.00 2.85 1.21
Total Noncurrent Liabilities		 59 32 50 92
Long-Term Debt		 50 21 29 77
Noncurrent Employee Benefit Liabilities		 0.78 0.65 0.70 0.78
Other Noncurrent Operating Liabilities		 7.66 11 21 13
Total Equity & Noncontrolling Interests		 107 73 380 224
Total Preferred & Common Equity		 77 73 380 224
Total Common Equity		 77 73 380 224
Common Stock		 122 161 530 496
Retained Earnings		 -45 -89 -150 -272
Other Equity Adjustments		 0.00 - - -0.08

Quarterly Balance Sheets for Abivax

No quarterly balance sheets for Abivax are available.

Annual Metrics And Ratios for Abivax

This table displays calculated financial ratios and metrics derived from Abivax's official financial filings.

Metric 2021 2022 2023 2024
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 13.37%
EBITDA Growth		 0.00% -48.00% -103.54% -26.97%
EBIT Growth		 0.00% -48.03% -103.14% -27.08%
NOPAT Growth		 0.00% -48.03% -103.14% -27.08%
Net Income Growth		 0.00% -35.24% -151.51% -11.62%
EPS Growth		 0.00% -23.71% -11.53% 23.61%
Operating Cash Flow Growth		 0.00% -14.20% -226.49% 19.02%
Free Cash Flow Firm Growth		 0.00% 0.00% -134.91% 21.87%
Invested Capital Growth		 0.00% 44.10% 89.88% 7.33%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 102.54% 93.68% 115.99% 101.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -45.01% -72.43% -72.19% -60.35%
Cash Return on Invested Capital (CROIC)		 0.00% -103.00% -141.39% -81.34%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -32.63% -60.58% -72.19% -60.35%
Return on Equity Simple (ROE_SIMPLE)		 -62.08% -89.42% -42.99% -81.28%
Net Operating Profit after Tax (NOPAT)		 -33 -49 -99 -125
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -32.27% -96.09% -63.44% -42.76%
Return On Investment Capital (ROIC_SIMPLE)		 - -42.38% -22.34% -38.68%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -47 -69 -141 -179
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -47 -69 -140 -178
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 2.80 2.98 1.21 2.06
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.44 28.66
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.84 2.68 1.50 2.36
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.48 0.58 0.16 0.44
Long-Term Debt to Equity		 0.47 0.28 0.08 0.34
Financial Leverage		 -0.44 -0.19 -0.45 -0.44
Leverage Ratio		 1.16 1.14 0.98 0.95
Compound Leverage Factor		 1.19 1.07 1.13 0.97
Debt to Total Capital		 32.24% 36.57% 13.90% 30.73%
Short-Term Debt to Total Capital		 0.45% 18.64% 7.42% 6.89%
Long-Term Debt to Total Capital		 31.79% 17.93% 6.48% 23.84%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 18.63% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 49.13% 63.43% 86.10% 69.27%
Debt to EBITDA		 -1.09 -0.61 -0.44 -0.56
Net Debt to EBITDA		 0.38 -0.19 1.55 0.28
Long-Term Debt to EBITDA		 -1.08 -0.30 -0.20 -0.43
Debt to NOPAT		 -1.55 -0.86 -0.62 -0.79
Net Debt to NOPAT		 0.55 -0.27 2.20 0.40
Long-Term Debt to NOPAT		 -1.53 -0.42 -0.29 -0.62
Altman Z-Score		 0.41 -2.49 0.84 -2.31
Noncontrolling Interest Sharing Ratio		 27.50% 16.36% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 3.53 1.02 3.49 2.45
Quick Ratio		 3.53 1.02 3.49 2.45
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -75 -176 -137
Operating Cash Flow to CapEx		 -95,846.09% 0.00% -1,207.53% -23,238.59%
Free Cash Flow to Firm to Interest Expense		 0.00 -9.96 -5.70 -7.81
Operating Cash Flow to Interest Expense		 -12.65 -7.75 -6.16 -8.75
Operating Cash Flow Less CapEx to Interest Expense		 -12.66 -7.71 -6.68 -8.79
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 59 86 163 175
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 26 77 12
Enterprise Value (EV)		 228 230 243 412
Market Capitalization		 217 217 461 461
Book Value per Share		 $5.01 $3.81 $8.83 $3.57
Tangible Book Value per Share		 ($0.45) ($1.00) $4.39 $0.26
Total Capital		 158 115 441 324
Total Debt		 51 42 61 100
Total Long-Term Debt		 50 21 29 77
Net Debt		 -18 13 -217 -50
Capital Expenditures (CapEx)		 0.05 -0.33 16 0.66
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.76 -6.68 -28 -27
Debt-free Net Working Capital (DFNWC)		 62 22 251 122
Net Working Capital (NWC)		 61 0.80 218 100
Net Nonoperating Expense (NNE)		 15 16 65 57
Net Nonoperating Obligations (NNO)		 -47 13 -217 -50
Total Depreciation and Amortization (D&A)		 0.34 0.52 0.78 1.14
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 43.07M 63.05M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($3.43) ($2.90)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 43.07M 63.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 62.93M 63.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -38 -99 -125
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -11.63 -9.23 -4.57 -10.18
NOPAT to Interest Expense		 -8.14 -6.46 -3.20 -7.13
EBIT Less CapEx to Interest Expense		 -11.64 -9.19 -5.08 -10.22
NOPAT Less CapEx to Interest Expense		 -8.15 -6.42 -3.71 -7.16
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -9.78% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Abivax

No quarterly metrics and ratios for Abivax are available.


Financials Breakdown Chart

Frequently Asked Questions About Abivax's Financials

When does Abivax's financial year end?

According to the most recent income statement we have on file, Abivax's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Abivax's net income changed over the last 3 years?

Abivax's net income appears to be on an upward trend, with a most recent value of -$182.43 million in 2024, rising from -$48.05 million in 2021. The previous period was -$163.43 million in 2023. View Abivax's forecast to see where analysts expect Abivax to go next.

What is Abivax's operating income?
Abivax's total operating income in 2024 was -$179.05 million, based on the following breakdown:
  • Total Gross Profit: -$6.16 million
  • Total Operating Expenses: $172.89 million
How has Abivax's revenue changed over the last 3 years?

Over the last 3 years, Abivax's total revenue changed from $0.00 in 2021 to -$6.16 million in 2024, a change of -616,298,500.0%.

How much debt does Abivax have?

Abivax's total liabilities were at $160.40 million at the end of 2024, a 16.0% increase from 2023, and a 93.9% increase since 2021.

How much cash does Abivax have?

In the past 3 years, Abivax's cash and equivalents has ranged from $28.83 million in 2022 to $278.70 million in 2023, and is currently $149.28 million as of their latest financial filing in 2024.

How has Abivax's book value per share changed over the last 3 years?

Over the last 3 years, Abivax's book value per share changed from 5.01 in 2021 to 3.57 in 2024, a change of -28.8%.


Related Companies

This page (NASDAQ:ABVX) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners
NEW LAW: Congress Approves Setup For Digital Dollar?
Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...
Goldco Precious Metals | Sponsoredtc pixel
If You Keep Cash In A U.S. Bank Account… Read This NOW
The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...
Banyan Hill Publishing | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...
Brownstone Research | Sponsoredtc pixel
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...
Angel Publishing | Sponsoredtc pixel
Move $1,000 into this stock before Nov 6
The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...
Altimetry | Sponsoredtc pixel
$4,200 gold is nice ... but here’s what most gold bugs are missing
Gold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...
Weiss Ratings | Sponsoredtc pixel
Buy UBER immediately
BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...
Chaikin Analytics | Sponsoredtc pixel